L’anticorps anti-Ret Proto-Oncogene Polyclonal Lapin est utilisé pour la détection de Ret Proto-Oncogene dans des échantillons de Humain, Souris, Rat et Singe. Il a été validé pour WB et IHC.
RET
Reactivité: Humain
WB
Hôte: Lapin
Polyclonal
RB17715
unconjugated
Indications d'application
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000,IHC 1:50-300
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Date de péremption
12 months
Antigène
Ret Proto-Oncogene (RET)
Autre désignation
Ret
Sujet
RET, CDHF12, CDHR16, PTC, RET51, Proto-oncogene tyrosine-protein kinase receptor Ret, Cadherin family member 12, Proto-oncogene c-RetRET (ret proto-oncogene), a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. RET plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in RET are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for RET. Additional transcript variants have been described but their biological validity has not been confirmed.